It has been nearly 9years since the FDA (Food and Drug Administration) approved the first
anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other …

Angiogenesis has become an attractive target for cancer therapy since the US Food and
Drug Administration (FDA) approved the first angiogenesis inhibitor (bevacizumab) for the …

Neo-angiogenesis plays a key role in colorectal cancer, with the vascular endothelial growth
factor family proteins and their receptors in particular triggering multiple signaling networks …

Abstract Since Judah Folkman hypothesized in 1971 that angiogenesis is required for solid
tumor growth, numerous studies have been conducted to unravel the angiogenesis process …

The importance of vascular endothelial growth factor (VEGF) as a regulator of normal and
tumor blood vessel growth has been increasingly characterized over the past two decades …

Introduction: Anti-angiogenetic agents are currently the standard of care in metastatic CRC
patients. Bevacizumab, aflibercept, regorafenib and recently ramucirumab have significantly …

Angiogenesis plays a crucial role in facilitating tumor growth and the metastatic process, and
it is the result of a dynamic balance between pro-angiogenic factors, like vascular …

Angiogenesis plays an essential role in tumor growth, invasion and metastasis. After initial
pessimism about the usefulness of the antiangiogenic therapeutic approach for cancer …

Tumor growth requires induction of an angiogenic program, and targeting of this program
with antiangiogenic drugs shows an impact on tumor progression. However, although they …

Angiogenesis is a hallmark of tumor development and metastasis and is now a validated
target for cancer treatment. However, the survival benefits of antiangiogenic drugs have thus …